29 April 2021 | 07:47am
StockMarketWire.com - medical technology company Convatec reported an 8.7% rise in revenue in the first quarter, led by strong growth in its advanced wound care and infusion care business.
For the three months ended March 2021, revenue rose 8.7% to $500 million year-on-year.
Advanced Wound Care revenue was up 8.8% on a reported basis, while Ostomy Care, its second largest business was up 6.7%.
Infusion Care revenue increased 13.9%, and continence & critical care revenue was up 7.4%.
Looking ahead, the company maintained its full year outlook, citing ongoing macro uncertainties.
For 2021, organic revenue growth is expected to be between 3% and 4.5%.
Story provided by StockMarketWire.com
5 March 2021 | 08:15am
StockMarketWire.com - Medical products maker ConvaTec reported a rise in annual profit on higher revenue and margins .
For the year ended 31 December 2020, pre-tax profit rose to $174.7 million from $8.9 million year-on-year as revenue rose 3.7% to $1,894.3 million.
Gross margin grew to 59.5% from 59%, while earnings before interest and tax fell 1.1% to $350 million.
The company proposed a dividend of 3.983 cents to take full-year dividend to 5.7 cents, in line with the prior year.
Looking ahead, the company expects to see 2021 organic revenue growth of between 3% to 4.5% and a constant currency adjusted EBIT margin of 18% to 19.5%.
At 8:15am: [LON:CTEC] Convatec Group PLC share price was 0p at 204.2p
5 March 2021 | 12:00pm
StockMarketWire.com - The FTSE 100 was back in positive territory by lunchtime helped by oil price driven strength in the energy sector and a slump in sterling. At midday the index was up 0.4% to 6,675.18.
US futures pointed to a flat open on Wall Street, after yesterday s heavy selling, with the monthly US jobs report in focus.
UK bourse operator London Stock Exchange has tumbled 9.4% to £86.00 after it reported an increase in annual profit on higher revenue in its information services and post-trade clearing business.
For the year ended 31 December, pre-tax profit increased to £685 million as revenue rose 3% to £2,124 million.